New drug CT-179 for people with glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new drug called CT-179 for people with glioblastoma, an aggressive type of brain cancer. The drug targets a protein that helps cancer cells grow, and the goal is to see if it is safe and whether it can slow the tumor down.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer) that is either new or has returned.
- You should be able to take care of yourself and walk around (this is measured by a score of 70 or higher on a performance scale).
- Your organs must be working well enough to handle the study drug.
- You must be able to swallow tablets.
- If you can become pregnant, you must agree to use effective contraception during the study.
- You cannot have certain other serious medical conditions, such as uncontrolled bleeding in the brain, or be taking certain medications like bevacizumab.
- You cannot have had an experimental treatment within the last 30 days.
- You cannot have significant stomach or bowel problems that would affect how the drug is absorbed.
- You cannot be taking more than 4 mg per day of dexamethasone (a steroid) within the week before starting the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (KH617) for people whose glioblastoma has returned after the first round of standard treatment. The drug is hoped to slow or stop the tumor's growth. You must have a specific genetic marker (MGMT unmethylated) and be in fairly good health to join.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
This trial tests a new drug called ACT001 for people with recurrent glioblastoma (a type of brain cancer) whose tumors have a specific marker (STAT3-high). The drug targets that marker to try to stop the tumor from growing.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
This trial tests a new drug called CM93 that targets a specific change (EGFR) in recurrent glioblastoma, a type of brain cancer. The goal is to see if it can slow or stop tumor growth and to find the best dose.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.